10-Q: CV Sciences Reports Q1 2025 Results: Revenue Declines Amid Strategic Shifts

Sentiment:

Quarterly Report 14 May 2025 4:50 PM

CV Sciences reports a decrease in net product sales for Q1 2025, alongside strategic cost reductions and ongoing efforts to secure additional funding.

Capital raiseManagement anticipates that the Company will be dependent, for the near future, on additional investment capital to fund our operations and growth initiatives.The Company intends to position itself so that it will be able to raise additional funds through the capital markets, issuance of debt, and/or securing lines of credit in order to continue its operations.

Worse than expectedNet product sales decreased by 9.9% to $3.606 million in Q1 2025 compared to $4.002 million in Q1 2024.Gross profit decreased by 10.5% to $1.658 million in Q1 2025 compared to $1.853 million in Q1 2024.

Summary

CV Sciences, Inc. reported its financial results for the quarter ended March 31, 2025.
Net product sales decreased to $3.606 million from $4.002 million in the same period last year, primarily due to lower sales volume.
The company's gross profit decreased to $1.658 million from $1.853 million year-over-year.
Operating expenses decreased to $1.647 million from $2.473 million, driven by reduced selling, general, and administrative expenses.
The company reported a net loss of $109,000, an improvement from the $628,000 net loss in Q1 2024.
CV Sciences is focusing on strategic cost reductions, including employee headcount and vendor spending.
The company is actively seeking additional investment capital to fund operations and growth initiatives.
In February 2025, CV Sciences received net proceeds of $1.2 million from a secured promissory note.
The company's financial operating results and accumulated deficit raise substantial doubt about its ability to continue as a going concern.
The company derecognized a contingent liability of $0.5 million during the three months ended March 31, 2025 related to payroll taxes.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company reports an improved net loss and reduced operating expenses, it also faces declining sales, a challenging regulatory environment, and substantial doubt about its ability to continue as a going concern. The need for additional capital raises further contributes to the mixed sentiment.

Positives

The company's net loss improved significantly, decreasing from $628,000 in Q1 2024 to $109,000 in Q1 2025.
Operating expenses were substantially reduced, falling from $2.473 million to $1.647 million.
The company secured $1.2 million in net proceeds from a secured promissory note in February 2025.
The company derecognized a contingent liability of $0.5 million during the three months ended March 31, 2025 related to payroll taxes.
35.0% of net revenue for the first quarter 2025 was from new products launched since January 1, 2023.

Negatives

Net product sales decreased by 9.9% to $3.606 million in Q1 2025 compared to $4.002 million in Q1 2024.
Gross profit decreased by 10.5% to $1.658 million in Q1 2025 compared to $1.853 million in Q1 2024.
The company's financial operating results and accumulated deficit raise substantial doubt about its ability to continue as a going concern.
The company generated negative cash flows from operations of $0.1 million for the three months ended March 31, 2025, and had an accumulated deficit of $87.1 million as of March 31, 2025.

Risks

The company faces intense competition in a fragmented market due to the lack of a clear regulatory framework.
The company's ability to continue as a going concern is in substantial doubt due to financial operating results and accumulated deficit.
The company is dependent on additional investment capital to fund operations and growth initiatives, with no assurance of obtaining such capital.
Differing state regulations regarding CBD products could adversely impact the company's revenue and earnings.
Increased tariffs on imports from China could force the company to raise prices or make changes to its operations.
An emergency order in California effectively banning the sale of hemp products containing detectable amounts of THC or certain other cannabinoids in California had a negative impact on operating results for the three months ended March 31, 2025 and is expected to continue to have a negative impact on the business going forward.

Future Outlook

The company anticipates being dependent on additional investment capital to fund operations and growth initiatives and will continue to make and implement strategic cost reductions. The company intends to position itself to raise additional funds through capital markets, issuance of debt, and/or securing lines of credit.

Management Comments

We are a consumer wellness company specializing in hemp extracts and other proven, science-backed, natural ingredients and products, which are sold through a range of sales channels from B2B to B2C.
With the help of Maxim, the Company intends to continue to build an efficient and cost effective consumer products platform and continue to evaluate inbound and outbound merger, sale, acquisition or other opportunities for the Company.

Industry Context

The company operates in a fragmented and highly competitive market due to the lack of a clear regulatory framework for CBD products. Differing state regulations and uncertainty among regulatory agencies pose challenges to the company's operations and interstate commerce.

Comparison to Industry Standards

The document does not provide enough information to make a detailed comparison to industry standards.
Without specific benchmarks or competitor data, it's difficult to assess whether CV Sciences' performance is above, below, or in line with industry averages.
A more comprehensive analysis would require comparing CV Sciences' financial metrics (e.g., revenue growth, gross margin, operating expenses) to those of similar companies in the CBD and nutraceuticals space.
Comparable companies could include Charlotte's Web, Canopy Growth Corporation, or other publicly traded firms with a significant presence in the CBD market.
Additionally, comparing CV Sciences' performance to industry reports and market research data could provide valuable insights into its competitive positioning.

Legal Proceedings

The Company initiated an arbitration with JAMS asserting claims against its long-time legal counsel, Procopio, seeking to recover damages resulting from reliance on Procopio's advice and guidance.

Related Party Transactions

The company derecognized a contingent liability of $0.5 million during the three months ended March 31, 2025 related to payroll taxes associated with the RSU release to founder in 2019.

Stakeholder Impact

Shareholders face uncertainty due to the company's going concern status and dependence on additional capital.
Employees may be affected by ongoing cost reductions, including potential headcount reductions.
Customers may experience changes in product offerings and pricing due to market conditions and regulatory changes.
Suppliers and creditors face increased risk due to the company's financial instability.

Next Steps

The company will continue to innovate new products, build brand awareness, and make significant investments in its business strategy.
The company intends to make additional acquisitions to further diversify its product offerings.
The company will continue to work towards increasing revenue and operating cash flows to meet its future liquidity requirements.
The company will continue to implement strategic cost reductions.

Key Dates

Date	Description
December 9, 2010	CV Sciences, Inc. was incorporated under the name Foreclosure Solutions, Inc. in the State of Texas.
January 29, 2013	The Company subsequently changed its name to CannaVest Corp. (Texas).
July 25, 2013	The Company merged with and into its wholly-owned Delaware subsidiary, CannaVest Corp (Delaware), to effectuate a change in the Company's state of incorporation from Texas to Delaware.
April 23, 2014	A purported class action was filed in the Southern District of New York (the Sallustro Case).
March 17, 2015	Michael Ruth filed a shareholder derivative suit in Nevada District Court alleging breach of fiduciary duty and gross mismanagement (the Ruth Complaint).
January 4, 2016	The Company filed a Certificate of Amendment of Certificate of Incorporation reflecting its corporate name change to CV Sciences, Inc., effective on January 5, 2016.
January 5, 2016	Corporate name change to CV Sciences, Inc. became effective.
January 22, 2019	Mona's resignation from the Company.
July 2, 2019	The court in the Sallustro Case entered a final order dismissing the complaint with prejudice.
September 20, 2019	Defendants filed a motion to dismiss the Ruth Complaint.
December 3, 2019	Michelene Colette and Leticia Shaw filed a putative class action complaint in the Central District of California, alleging the labeling on the Company's products violated the Food, Drug, and Cosmetic Act of 1938 (the Colette Complaint).
November 24, 2020	The court issued a ruling denying the motion to dismiss on November 24, 2020.
December 11, 2020	A Third Amended Complaint was filed on December 11, 2020 substituting Otilda Lamont as plaintiff.
January 11, 2021	The Company filed an answer to the Ruth complaint on January 11, 2021.
January 2022	The parties agreed to a settlement in principle in January 2022 whereby the Company agreed to make certain corporate governance reforms in exchange for dismissal of the lawsuit.
June 1, 2022	Plaintiff filed a motion for preliminary approval of proposed settlement on June 1, 2022.
February 7, 2023	The court granted preliminary approval of the proposed settlement on February 7, 2023.
January 26, 2023	The FDA announced that it does not intend to pursue rulemaking allowing the use of cannabidiol products in dietary supplements or conventional foods.
February 13, 2023	Plaintiffs filed a status report with the court asking to have the stay lifted.
May 15, 2023	A hearing seeking final approval of the proposed settlement was held on May 15, 2023, and the court indicated it would likely approve the proposed settlement and reschedule the hearing with regard to plaintiff's motion for attorney's fees.
June 1, 2023	The Company's shareholders approved the adoption of a new 2023 Equity Incentive Plan (the 2023 Plan), and the Company adopted the 2023 Plan.
June 23, 2023	The Company received notice of a court order dated May 23, 2023 without any hearing, granting plaintiff's motion for attorney's fees and expenses of approximately $ 250,000.
December 7, 2023	The Company acquired Cultured Foods Sp. z.o.o.
May 1, 2024	The Company and plaintiff executed a stipulation for the payment of the plaintiff's attorney's fees and expenses over the course of approximately eighteen months subject to a confession of judgment.
May 8, 2024	The Company entered into a Membership Interest Purchase Agreement (the Softgels Purchase Agreement), by and among the Company, Elevated Softgels, LLC, a Delaware limited liability company (Elevated Softgels), Clayton J. Montgomery (a Softgels Member), Chris Fagan, Andrew Kester, and Timothy McGreer, pursuant to which the Company purchased all of the outstanding equity interests in Elevated Softgels, resulting in Elevated Softgels becoming a wholly owned subsidiary of the Company (the Softgels Acquisition).
May 13, 2024	The Softgels Acquisition closed on May 13, 2024.
August 2024	The Company engaged Maxim Group LLC as a non-exclusive financial advisor and investment banker.
July 3, 2024	The Company entered into a note purchase agreement with Streeterville, pursuant to which the Company issued and sold to Streeterville a Secured Promissory Note (the 'Streeterville Note') in the original principal amount of $ 1.2 million.
October 2024	The Company entered into a new lease agreement for its manufacturing facility in Poland.
October 2024	The Company entered into a financing agreement with First Insurance Funding in order to fund a portion of its insurance policies for the upcoming policy year.
November 21, 2024	The Company announced that it entered into a definitive stock purchase agreement (the Purchase Agreement') by and among the Company, Extract Labs Inc., a Colorado corporation (Extract Labs), Craig Henderson (Henderson) and Higher Love Wellness Company, LLC (Higher Love) and together with Extract Labs, Henderson, and Higher Love the Sellers to purchase all of the outstanding shares of Extract Labs from the Sellers.
December 31, 2024	The Company performed its annual goodwill impairment analysis following the steps laid out in ASC 350-20-35-3C.
January 10, 2025	Procopio terminated the Company as a client, ending the Company's 12-year relationship with Procopio as its legal counsel.
February 5, 2025	The Company received an electronic mail message from Henderson indicating that the Sellers were unable to move forward with the closing under the Purchase Agreement due to the alleged failure to receive a bank consent and were apparently terminating the Purchase Agreement.
February 12, 2025	The Company initiated an arbitration with JAMS asserting claims against its long-time legal counsel, Procopio.
February 12, 2025	The Company entered into a securities purchase agreement with an institutional investor (the Investor), pursuant to which the Company issued and sold to the Investor a secured promissory note in the original principal amount of $ 1,600,000 (the Note).
February 2025	The Company entered into a new lease agreement for its existing Elevated Softgels manufacturing facility.
April 2025	JAMS appointed an arbitrator to the case.
April 1, 2025	The lease commenced on April 1, 2025.
April 15, 2025	The statute of limitations for employer and employee Medicare portion of FICA taxes expired.
May 11, 2025	As of May 11, 2025, the issuer had 184,263,663 shares of issued and outstanding common stock, par value $0.0001 per share.
May 14, 2025	Date of report.
June 12, 2025	The Company is required to make monthly repayments to the Investor of $ 106,667 starting on June 12, 2025.
August 12, 2026	The Note is due and payable on August 12, 2026.
September 30, 2026	The lease term is for two years and expires on September 30, 2026.

Keywords

CV Sciences, CBD, hemp extracts, financial results, Q1 2025, net sales, gross profit, operating expenses, net loss, going concern, capital raise, Elevated Softgels, Cultured Foods

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.